[Proteic profiling SELDI-TOF and breast cancer: clinical potential applications]

Med Sci (Paris). 2007 Mar:23 Spec No 1:23-6. doi: 10.1051/medsci/2007231s23.
[Article in French]

Abstract

Significant advances in early diagnosis, prognostic markers, therapeutic response and toxic effect indicators, together with the identification of new potential drug targets, have improved the survival of patients with breast cancer. Proteomic technologies, including SELDI-TOF (surface enhanced laser desorption/ionization-time of flight) mass spectrometry, are emerging tools that may contribute to better reach these key objectives.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / blood*
  • Breast Neoplasms / blood*
  • Breast Neoplasms / diagnosis
  • Early Diagnosis
  • Female
  • Humans
  • Neoplasm Proteins / blood*
  • Prognosis
  • Proteomics / methods*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / instrumentation
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods*

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins